Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | AOC2 | O75106 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026295 | 0.83 | TSHR (0.47) | TSHRNPC1CACNA1GKCNH2MAOB | |
| SCHEMBL27841646 | 0.81 | TSHR (0.46) | TSHRNPC1CACNA1GKCNH2MAOB | |
| SCHEMBL11023506 | 0.80 | TSHR (0.50) | TSHRNPC1CACNA1GKCNH2MEN1 | |
| SCHEMBL11612984 | 0.80 | TSHR (0.50) | TSHRNPC1CACNA1GKCNH2MEN1 | |
| SCHEMBL1840653 | 0.79 | LMNA (0.64) | TSHRNPC1CACNA1GKCNH2MEN1 | |
| SCHEMBL1759561 | 0.79 | CYP2C9 (0.56) | TSHRMEN1KMT2AMAPT | |
| SCHEMBL1835550 | 0.79 | LMNA (0.64) | TSHRNPC1CACNA1GKCNH2MEN1 | |
| SCHEMBL8479002 | 0.79 | TDP1 (0.48) | TSHRNPC1MAOBMAOAAPP | |
| SCHEMBL6273026 | 0.79 | LMNA (0.64) | TSHRNPC1CACNA1GKCNH2MEN1 | |
| SCHEMBL8747584 | 0.79 | CYP1A2 (0.53) | TSHRNPC1CACNA1GKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3666757-A1 | PROCESS FOR PREPARING A PIPERIDIN-4-ONE | Karl-Franzens-Universität Graz (AT) | 2020-06-17 | — | — | EP | claimed |
| EP-3666757-A1 | PROCESS FOR PREPARING A PIPERIDIN-4-ONE | Karl-Franzens-Universität Graz (AT) | 2020-06-17 | — | — | EP | disclosed |
| US-8765728-B2 | [1,5]-diazocin derivatives | MELLITECH (FR) | 2014-07-01 | — | — | US | disclosed |
| CN-102812011-A | [1,5] -diazacyclo-octatetraene derivative | MELLITECH | 2012-12-05 | — | — | CN | disclosed |
| EP-2501685-A1 | [1,5]-DIAZOCIN DERIVATIVES | Mellitech (FR) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | MELLITECH (FR) | 2012-09-06 | — | — | US | disclosed |
| WO-2011058193-A1 | [1,5]-DIAZOCIN DERIVATIVES | MELLITECH (FR) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | IAPP, INSR, GLP1R | TSHR 2640/4885NPC1 510/4885CACNA1G 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.